8th March 2018; 07:00 PST; 10:00 EST; 15:00 GMT; 16:00 CET
One of the biggest challenges facing the cell and gene therapy industry is how to effectively scale these promising therapies whilst maintaining product quality and minimizing costs of manufacture. Join this webinar with Dr Giulia Detela, VivaBioCell, to hear about the latest advances in tackling the issue of scalability as she discusses:
- The unique scale-out challenges of autologous cell therapy manufacture;
- Equipment criteria and requirements for autologous cell therapy product manufacture;
- First-hand experience of working towards CMC and GMP readiness in your product development;
- A specific case study utilizing the NANT 001 system in an autologous cell therapy process for osteoarthritis treatment.
Following the presentation, you will have the opportunity to pose your questions to our expert speaker.
Webinar attendance is free of charge, but places are limited, so register today to guarantee your participation. If you’re not sure if you’re free on the day, please register anyway and we will send you the link to the recorded webinar as soon as it is live.
By registering to view this Webinar you are also signing up as a member of Cell & Gene Therapy Insights and agree to be contacted by our sponsors. We will email you a username and password so you can read all our open access content.
Dr Giulia Detela
Process Design Manager, VivaBioCell S.p.A., Italy
Dr Giulia Detela is Process Design Manager at VivaBioCell S.p.A., a company of the NantWorks group, which develops novel automated systems for cell-based product manufacturing. She supports the EU/US tech transfer activities related to cell manufacturing for regenerative medicine and immunotherapy applications. She also ensures that products and processes are compliant to regulatory requirements, performs risk and costs analyis, whilst providing support to the Business Development activities. Giulia was previously a Process Development Scientist at The Cell and Gene Therapy Catapult, supporting the development of candidate advanced therapy products and associated CMC quality requirements. She obtained her PhD in 2015 with a project aimed at discovering strategies to enhance the engraftment and angiogenic potential of human mesenchymal stromal cells within ischemic tissues at the Regenerative Medicine and Bioprocessing Unit of the Department of Biochemical Engineering at University College London (UCL).